证券代码：300158 证券简称：振东制药 公告编号：2023-066 山西振东制药股份有限公司 关于第三期员工持股计划实施进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本次员工持股计划尚未实施完毕，公司将持续关注员工持股计划的 实施进展情况，按照相关规定及时履行信息披露义务。请投资者关注相 关公告并注意投资风险。 特此公告。 山西振东制药股份有限公司董事会 山西振东制药股份有限公司（以下简称"公司"）于 2023 年 5 月 29 日召开第五届董事会第十一次会议及第五届监事会第九次会议、2023 年 6 月 15 日召开 2023 年第二次临时股东大会，会议审议通过了《关于 <山西振东制药股份有限公司第三期员工持股计划（草案）>及其摘要的 议案》、《关于<山西振东制药股份有限公司第三期员工持股计划管理 办法>的议案》及其他相关议案。相关具体内容详见公司于 2023 年 5 月 30 日、2023 年 6 月 15 日在巨潮咨询网（http://www.cninfo.com.cn）披 露的相关公告。 根据中国证监会《关于上市公司实施员工持股计划试 ...

证券代码：300158 证券简称：振东制药 公告编号：2023-065 山西振东制药股份有限公司 关于股东股份解押及质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"、或"本公司"） 于近日接到控股股东山西振东健康产业集团有限公司（以下简称 "振东集团"）通知，获悉其所持有的本公司部分股份做了解押及质 押，具体事项如下： 一、股东股份解押基本情况 1、本次股份解押基本情况 | 股东 | 是否为控 | | 本次解除质押 | 占其所持 | 占公司总 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 股股东 | | 股份数量（股） | 股份比例 | 股本比例 | | | | | 振东 集团 | | 是 | 15,730,000 | 5.21% | 1.53% | 2022.11.21 | 2023.10.26 | 中国银行股份有限公司 长治市分行 | 二、股东股份质押基本情况 1、本次股份质押基本情 ...

Financial Performance - The company's revenue for Q3 2023 was ¥850,856,602.59, a decrease of 20.74% compared to the same period last year[4] - The net profit attributable to shareholders was -¥15,416,615.29, representing a significant decline of 15,654.59% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥20,375,356.75, a decrease of 601.05% compared to the previous year[4] - Total operating revenue for the current period was ¥2,783,745,444.64, a decrease of 0.6% compared to ¥2,799,161,844.04 in the previous period[26] - Net profit for the current period was -¥4,134,073.59, compared to a net profit of ¥20,892,626.21 in the previous period, indicating a significant decline[28] - The company reported a comprehensive income total of -¥35,476,894.88, contrasting with a positive comprehensive income of ¥22,236,185.47 in the previous period[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,140,744,839.96, down 6.26% from the end of the previous year[4] - Total assets as of September 30, 2023, amounted to CNY 6,140,744,839.96, a decrease from CNY 6,550,914,912.15 at the beginning of the year[20] - Current assets totaled CNY 4,496,055,422.90, down from CNY 4,883,273,988.04 at the start of the year, indicating a decline of approximately 7.9%[20] - Total liabilities decreased to CNY 1,644,689,417.06 from CNY 1,667,640,924.11, showing a reduction of about 1.5%[22] - The company’s total liabilities decreased to ¥952,930,953.41 from ¥1,327,624,130.74, a reduction of approximately 28.3%[24] - The total equity attributable to shareholders decreased to ¥5,221,936,937.89 from ¥5,254,153,964.09, a decline of about 0.6%[24] Cash Flow - The cash flow from operating activities showed a net outflow of -¥223,264,687.72, a decrease of 134.23% compared to the same period last year[15] - Cash flow from operating activities showed a net outflow of -¥223,264,687.72, worsening from -¥95,319,080.77 in the previous period[31] - The net cash flow from investment activities was 633,514,376.00, a decrease of 76.92% compared to the previous period's 2,746,375,586.41[33] - Total cash and cash equivalents at the end of the period amounted to 938,160,243.88, compared to 1,161,485,311.55 at the end of the previous period[33] - The net cash flow from financing activities was -155,812,178.68, an improvement from -2,673,692,007.29 in the previous period[33] Income and Expenses - The company reported a significant increase in credit impairment losses, amounting to -¥21,635,427.84, up 3816.78% year-on-year[13] - The investment income decreased to ¥23,736,148.67, down 59.16% compared to the previous year[13] - The company experienced a 53.16% decline in other income, totaling ¥33,345,000.05 for the quarter[13] - Total operating costs decreased to ¥2,795,510,880.16 from ¥2,858,356,894.01, reflecting a reduction of approximately 2.2%[26] - The company reported a decrease in other income to ¥33,345,000.05 from ¥71,194,911.57, a decline of about 53%[28] Shareholder Information - The number of common shareholders at the end of the reporting period was 62,957, with the largest shareholder holding 29.41% of the shares[17] - The largest shareholder, Shanxi Zhendong Health Industry Group Co., Ltd., held 302,230,191 shares, with 160,560,000 shares pledged[17] Research and Development - The company has ongoing research and development efforts, with development expenditures recorded at CNY 200,825,198.94[22] - Research and development expenses increased to ¥137,283,367.79 from ¥124,149,410.17, reflecting a growth of approximately 10.6%[26] Market Strategies - The company is exploring market expansion strategies, although specific details were not disclosed in the report[21]

山西振东制药股份有限公司 关于第三期员工持股计划实施进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：300158 证券简称：振东制药 公告编号：2023-062 为 5.80 元/股。 本次员工持股计划尚未实施完毕，公司将持续关注员工持股计划的 实施进展情况，按照相关规定及时履行信息披露义务。请投资者关注相 关公告并注意投资风险。 特此公告。 山西振东制药股份有限公司董事会 2023 年 10 月 13 日 山西振东制药股份有限公司（以下简称"公司"）于 2023 年 5 月 29 日召开第五届董事会第十一次会议及第五届监事会第九次会议、2023 年 6 月 15 日召开 2023 年第二次临时股东大会，会议审议通过了《关于 <山西振东制药股份有限公司第三期员工持股计划（草案）>及其摘要的 议案》、《关于<山西振东制药股份有限公司第三期员工持股计划管理 办法>的议案》及其他相关议案。相关具体内容详见公司于 2023 年 5 月 30 日、2023 年 6 月 15 日在巨潮咨询网（http://www.cninfo.com.cn）披 露的 ...

关于股东股份解押及质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"、或"本公司"） 于近日接到控股股东山西振东健康产业集团有限公司（以下简称 "振东集团"）通知，获悉其所持有的本公司部分股份做了解押及质 押，具体事项如下： 一、股东股份解押基本情况 1、本次股份解押基本情况 证券代码：300158 证券简称：振东制药 公告编号：2023-061 山西振东制药股份有限公司 | 股东 | 是否为控 | | 本次解除质押 | 占其所持 | 占公司总 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 股股东 | | 股份数量（股） | 股份比例 | 股本比例 | | | | | 振东 集团 | | 是 | 12,690,000 | 4.20% | 1.24% | 2022.11.21 | 2023.9.22 | 中国银行股份有限公司 长治市分行 | 二、股东股份质押基本情况 1、本次股份质押基本情况 ...

截至本公告披露日，公司第三期员工持股计划通过二级市场以集中 竞价交易方式累计买入公司股票 12,637,900 股，占公司总股本的 1.2300%，成交总金额为 72,863,314 元（不含交易费用），成交均价约 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"）于 2023 年 5 月 29 日召开第五届董事会第十一次会议及第五届监事会第九次会议、2023 年 6 月 15 日召开 2023 年第二次临时股东大会，会议审议通过了《关于 <山西振东制药股份有限公司第三期员工持股计划（草案）>及其摘要的 议案》、《关于<山西振东制药股份有限公司第三期员工持股计划管理 办法>的议案》及其他相关议案。相关具体内容详见公司于 2023 年 5 月 30 日、2023 年 6 月 15 日在巨潮咨询网（http://www.cninfo.com.cn）披 露的相关公告。 根据中国证监会《关于上市公司实施员工持股计划试点的指导意见》 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规 范运作》的相关要求，现将公司第三 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥1,932,888,842.05, representing a 12.01% increase compared to ¥1,725,633,992.62 in the same period last year[24]. - Net profit attributable to shareholders decreased by 40.99% to ¥14,542,410.37 from ¥24,645,360.27 year-on-year[24]. - The net cash flow from operating activities was negative at ¥107,792,905.41, a decline of 421.48% compared to the previous year's negative cash flow of ¥20,670,513.89[24]. - Basic earnings per share fell by 40.83% to ¥0.0142 from ¥0.0240 in the previous year[24]. - Total assets decreased by 5.34% to ¥6,200,999,812.06 from ¥6,550,914,912.15 at the end of the previous year[24]. - The net assets attributable to shareholders slightly decreased by 0.32% to ¥5,237,360,643.38 from ¥5,254,153,964.09 at the end of the previous year[24]. - The company reported a significant reduction in income tax expenses, which fell by 47.38% to ¥17,280,721.86 from ¥32,842,318.07[67]. - The cash and cash equivalents increased by 34.90% to ¥163,619,639.15, compared to an increase of ¥121,293,174.71 in the previous year[67]. - The company reported a net loss of CNY 1,063,821.26 for the period, compared to a loss of CNY 15,606,231.63 previously[193]. Market and Industry Insights - The pharmaceutical industry in China is expected to grow, with the innovative drug market projected to reach CNY 778.9 billion in 2023, up from CNY 678.5 billion in 2022, reflecting a growth rate of approximately 15.3%[32]. - The hair medical service market in China is predicted to reach CNY 56.3 billion by 2025, more than doubling from CNY 23.4 billion in 2021[33]. - The company ranked 64th in the 2021 National Pharmaceutical Industry Top 100 and 52nd in the 2022 China Chemical Pharmaceutical Enterprises Top 100[35]. - The male population suffering from hair loss in China is approximately 163 million, representing about 65.2% of the total affected population[33]. Research and Development - The company has a significant focus on R&D in oncology, dermatology, digestive, urology, and cardiovascular drugs, indicating a diverse product portfolio[36]. - The company has developed over 130 research projects and undertaken more than 50 national and provincial-level projects, emphasizing its commitment to innovation in drug development[60]. - The company has established a comprehensive R&D network with institutions such as the Chinese Academy of Medical Sciences and Tsinghua University, focusing on innovative drug development[48]. - The company has a strong focus on R&D for new products, particularly in the fields of oncology and cardiovascular drugs, enhancing its product portfolio[41]. Sales and Marketing Strategies - The company has established a specialized sales team and a unique marketing management model, covering 23 provinces, 5 autonomous regions, and 4 municipalities in China[42]. - The prescription drug sales focus on clinical self-operation, with coverage in 237 prefecture-level cities and 337 county-level cities, reaching over 20,000 medical terminals[43]. - The company actively explores online sales models, collaborating with major platforms like Alibaba, JD.com, and Pinduoduo, while also empowering offline chain terminal clients[45]. - The company has built a sales network that integrates both online and offline channels to enhance brand visibility and product accessibility[45]. - The company’s marketing strategy includes five major centers: clinical, OTC, three terminals, dermatology, and e-commerce, facilitating high-quality development across all channels[61]. Risk Management - The company has outlined potential risks and countermeasures in its management discussion section, which investors should pay attention to[5]. - R&D risks are significant, with the company focusing on enhancing collaboration with research institutions to mitigate uncertainties in new drug development[96]. - Quality risks are being addressed by strengthening quality management systems and implementing rigorous monitoring protocols throughout the production process[97]. - The company is facing policy risks due to stricter regulations and market pressures, which have led to increased competition and a need for strategic adjustments[95]. Environmental Compliance - The company has completed environmental protection assessments for all completed construction projects and obtained the necessary approvals[111]. - The company has maintained compliance with various environmental protection laws and industry standards[111]. - The total wastewater discharge from Shanxi Zhendong Pharmaceutical Co., Ltd. is 38,962.2 m³, with a chemical oxygen demand (COD) of 6.083 tons per year[115]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[124]. Corporate Governance - The company held its first temporary shareholders' meeting on April 14, 2023, with an investor participation rate of 30.63%[104]. - The annual shareholders' meeting on May 16, 2023, had a participation rate of 34.20%[104]. - The company has elected new independent directors and board members during the reporting period[106]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[108]. Related Party Transactions - The total amount of related party transactions for the first half of 2023 reached CNY 59.76 million, with a maximum expected amount of CNY 199.50 million for the year[143]. - The company’s related party transactions are primarily based on market prices, ensuring compliance with pricing principles[145]. - The company has established a robust framework for disclosing related party transactions, with all transactions disclosed on April 25, 2023[141]. Future Outlook - Future outlook includes continued investment in research and development to enhance product offerings and market competitiveness[159]. - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product portfolio[159]. - Shanxi Zhendong Pharmaceutical aims to maintain a growth trajectory in the pharmaceutical market through strategic partnerships and collaborations[159].

证券代码：300158 证券简称：振东制药 公告编号：2023-052 一、股东股份解押基本情况 1、本次股份解押基本情况 | 股东 | 是否为控 | 本次解除质押 | 占其所持 | 占公司总 | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 股股东 | 股份数量（股） | 股份比例 | 股本比例 | | | | | 振东 集团 | 是 | 10,500,000 | 3.47% | 1.02% | 2022.9.20 | 2023.8.17 | 中国银行股份有限公司 长治市分行 | 二、股东股份质押基本情况 1、本次股份质押基本情况 | 股东 | 是否为控 | 本次质押 | 占其所 | 占公司 | 是否 | 是否为 | 质押起 | 质押到 | | 质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 股股东 | 数量（股） | 持股份 | 总股本 | 为限 | 补充质 | 始日 | 期日 | 质权人 ...

证券代码：300158 证券简称：振东制药 公告编号：2023-051 截至本公告披露日，公司第三期员工持股计划通过二级市场以集中 竞价交易方式累计买入公司股票 7,714,800 股，占公司总股本的 0.7508%， 成交总金额为 44,522,543 元（不含交易费用），成交均价约为 5.77 元/ 股。 本次员工持股计划尚未实施完毕，公司将持续关注员工持股计划的 实施进展情况，按照相关规定及时履行信息披露义务。请投资者关注相 关公告并注意投资风险。 特此公告。 山西振东制药股份有限公司董事会 2023 年 8 月 15 日 山西振东制药股份有限公司 关于第三期员工持股计划实施进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山西振东制药股份有限公司（以下简称"公司"）于 2023 年 5 月 29 日召开第五届董事会第十一次会议及第五届监事会第九次会议、2023 年 6 月 15 日召开 2023 年第二次临时股东大会，会议审议通过了《关于 <山西振东制药股份有限公司第三期员工持股计划（草案）>及其摘要的 议案》、《关于<山西振东制药股份有限公 ...

证券代码：300158 证券简称：振东制药 公告编号：2023-050 山西振东制药股份有限公司 关于股东股份质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 1、公司控股股东振东集团本次股份质押与上市公司生产经营 需求无关。 2、公司控股股东振东集团未来半年内到期的质押股份为 48,610,000 股，占其所持股份比例 16.08%，占公司总股本比例 4.73%，对应融资余额 14,000 万元；未来一年内到期的质押股份为 84,400,000 股(不含半年内到期质押股份)，占其所持股份比例 27.93%，占公司总股本比例 8.21%，对应融资余额 29,000 万元。 公司控股股东振东集团具备资金偿还能力，还款资金来源包括营业 山西振东制药股份有限公司（以下简称"公司"或"本公司"）于 近日接到控股股东山西振东健康产业集团有限公司（以下简称"振 东集团"）通知，获悉其所持有的本公司部分股份做了质押，具体 事项如下： 一、股东股份质押基本情况 | 股东 | 是否为控 | 本次质押 | 占其所 持股份 | 占公司 总股本 | 是否为 | 是否为 补充 ...